Source: Annual Congress 2002 - Lung cancer: treatment
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
P. Remiszewski, K. Roszkowski-Sliz, B. Roszkowska-Sliz, E. Wiatr, J. Zych, E. Rowinska-Zakrzewska (Warsaw, Poland). The role of radiotherapy (RTH) in long-term survival limited disease (LD) small cell lung cancer (SCLC) patients (pts) treated in the National TB and Lung Diseases Research Institute. Eur Respir J 2002; 20: Suppl. 38, 2927

Member's Comments

No comment yet.

Related content which might interest you: Site of first progression (PR) differs between stage III NSCLC patients treated with simultaneous radiochemotherapy (RTCT) and those treated with radiotherapy (RT) alone following induction chemotherapy (CT) Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 Muldisciplinary conference (MDC), oncological program (OP) and practice guidelines (GL): The experience of the lung cancer (LC) clinic of a cancer hospital Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 Mortality in asymptomatic vs. symptomatic patients surgically treated for non-small cell lung cancer (NSCLC) Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts Year: 2013 Biological dosimetry in lung cancer (LC) patients treated with fractionated radiotherapy (RT) Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Lung cancer in Berlin – NET of the lung; analysis of subgroups and impact on survival (2000 – 2008) Source: Annual Congress 2013 –Epidemiology, screening and diagnosis of lung cancer Year: 2013 Oncogenic drivers (OD) and matched targeted agents (TA): Impact on overall survival in patients with lung adenocarcinoma (LA)? Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Major changes in men with non-small-cell lung cancer (NSCLC) in 10 years: The KBP-2000-CPHG and KBP-2010-CPHG cohorts Source: Annual Congress 2013 –Epidemiology, screening and diagnosis of lung cancer Year: 2013 Gefitinib in front line treatment of patients with NSCLC in the Czech Republic: Analysis of 113 patients Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Comorbitities, responses and survival in pts with NSCLC Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 Treatment and survival in patients with pulmonary carcinoid tumours; an updated analysis from the UK national lung cancer audit Source: International Congress 2015 – Thoracic oncology around the world: rare cases and local features Year: 2015 Analysis of overall survival (OS) in two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut) Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 Second primary lung cancer in squamous NSCLC patients: The Nancy Biobank's database Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 European treatment guidelines: small cell lung cancer (SCLC) Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Cancer recurrence in surgically treated non small cell lung cancer (NSCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 755s Year: 2006 Clinical outcome of Pembrolizumab (PEMB) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) – Reports from routine clinical care. Source: International Congress 2019 – Treatment of lung cancer Year: 2019 Prognostic systems in advanced non small cell lung cancer (NSCLC): A validation study by the European Lung Cancer Working Party (ELCWP) Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Evaluation of predictive and therapeutic value of WSX1/IL27 axis in non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Loss of heterozygosity of PTEN in patients with non-small cell lung cancer treated and not treated with neoadjuvant chemotherapy Source: Annual Congress 2013 –Genetics and genomics of lung disease Year: 2013